Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

445.21 +4.57 (+1.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,382,492
Open 442.00
Bid (Size) 435.10 (1)
Ask (Size) 454.76 (1)
Prev. Close 440.64
Today's Range 440.35 - 446.10
52wk Range 335.82 - 448.40
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga

Performance

YTD
+8.35%
+8.35%
1 Month
+13.26%
+13.26%
3 Month
+5.45%
+5.45%
6 Month
+27.02%
+27.02%
1 Year
+27.51%
+27.51%

More News

Read More
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Via Benzinga
Smart Money Is Betting Big In VRTX Options
Via Benzinga
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Via Benzinga
Exposures COVID-19
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
3 Cheap Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Exposures Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
Via The Motley Fool
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Stock Market Moves Toward Highs; Arista, Toast, Palantir Key Earnings Movers: Weekly Review
Via Investor's Business Daily
Will the Biotech Sector Shift From Lagger to Leader?
Via MarketBeat
Topics ETFs
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
Via Chartmill
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Markets In A Minute - "A Lack Of Further Progress"
Via Talk Markets
Topics Economy Workforce
Exposures Interest Rates Layoff
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Eye Fourth Positive Session Despite Hawkish Fed Remarks; Disney, Palantir Tumble; Treasury Yields Fall: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook
Via Investor's Business Daily
Vertex Reports First Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Biotech Stocks to Double Your Money in the Next 24 Months
Via InvestorPlace
3 No-Brainer Stocks to Buy in May
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.